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Abstract
Plasmablastic lymphoma (PBL) is an aggressive lymphoma commonly associated with human immunodeficiency
virus (HIV) infection. Herein we describe a rare case of PBL that spontaneously regressed. An 80-year-old man was
referred to our hospital owing to an exophytic gingival tumor in the right maxillary second molar region. He had
no significant past medical history, and a screening test for HIV was negative. Imaging showed that the tumor
measured 26 × 23 × 16 mm and was confined in the alveolar bone. The tumor was histologically comprised of
highly proliferative immunoblastic cells positive for CD138 and Epstein-Barr virus (EBV)-encoded RNA. Monoclonal
IgH chain gene rearrangement was detected via polymerase chain reaction. After biopsy and diagnosis of PBL, the
tumor began to decrease in size and had apparently disappeared at the time of surgery. There was no histological
evidence of a residual lesion in the surgical specimen. In conclusion, a minority of immunosenescence-associated
PBLs in the elderly should be recognized as a unique clinicopathological entity distinct from common aggressive
PBL.
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Background
Plasmablastic lymphoma (PBL) is a rare subtype of
diffuse large B-cell lymphoma (DLBCL), with a median
overall survival time of less than one year, initially docu-
mented in 1997 [1, 2]. PBL most commonly occurs in
the oral cavity of human immunodeficiency virus (HIV)-
positive individuals [2]. It is also associated with other
immunodeficiency states, such as iatrogenic immunosup-
pression due to administration of immunosuppressive
agents or immunosenescence in elderly adults [2]. Al-
though there seems to be no significant difference in the
prognosis of HIV-positive and HIV-negative PBLs [2], rare
PBLs in elderly HIV-negative patients without other
known immunodeficiency conditions have recently been
shown to possess unique clinicopathological features
including relatively indolent clinical behavior [3]. It has
been proposed that this age-related type of PBL be catego-
rized as PBL of the elderly (PBL-E) [3]. Epstein-Barr virus
(EBV) infection has been observed in all cases of PBL-E
[3], compared with 50 to 75 % of PBL cases associated
with the other immunodeficiency conditions [2].
Spontaneous regression of low-grade lymphoma report-
edly occurs in about 10 % of cases [4, 5], whereas spontan-
eous regression of aggressive lymphoma after biopsy has
rarely been observed [6]. Spontaneous regression of DLBCL
in patients with rheumatoid arthritis taking methotrexate
after immunosuppressant withdrawal has recently been
reported [7].
We herein describe a rare case of PBL-E that spontan-
eously regressed in the absence of any anti-neoplastic
treatment.
Case presentation
An 80-year-old man was referred to our hospital owing
to rapid growth of a gingival tumor in the right maxillary
second molar region. He had suffered from repeated
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gingival swelling of this region for 8 months before his
visit. Following a diagnosis of apical periodontitis, his
right maxillary second molar was extracted 6 weeks
before his visit. After an additional mucosal curettage to
treat unsuccessful wound healing, the gingiva at the
extraction site began to rapidly grow in size. The patient
had no significant past medical history including auto-
immune diseases and had not taken any immunosup-
pressive medication.
A physical examination revealed an exophytic gingival
tumor in the right maxillary second molar (Fig. 1a). This
soft elastic tumor was well circumscribed and bled eas-
ily. Computed tomography showed that the tumor mea-
sured 26 × 23 × 16 mm and was confined in the alveolar
bone. Progression of the tumor to the maxillary antrum
was not observed, nor was lymph node swelling. 18F-flu-
deoxyglucose positron emission tomography (FDG-PET)
showed elevated FDG uptake in the right maxilla with a
maximum standardized uptake value of 29.29 (Fig. 1b).
Abnormal FDG uptake at other sites was not noted.
Serum levels of lactate dehydrogenase (208 IU/L) and
soluble interleukin-2 receptor (177 U/mL) were normal,
and a screening test for HIV was negative. Serological
tests for EBV were also performed (Table 1).
A biopsy of the lesion showed a solid tumor with an
ulcertic surface (Fig. 2a). The tumor was characterized by
monomorphic neoplastic proliferation of large plasmacy-
toid and immunoblastic cells with prominent nucleoli
(Fig. 2b). Necrosis and giant cells with features similar to
those of Hodgkin and Reed/Sternberg cells were not
observed. Immunohistochemical immunophenotyping
analysis showed that the neoplastic cells were positive for
LCA and CD138 and negative for CD20, CD79a, PAX5,
CD3, CD5, CD10, CD15, CD56, ALK, LMP1, and EBNA2
(Fig. 2c, d). CD30 expression was not determined. Forty
percent of the tumor cells expressed c-Myc, and the Ki-67
labeling index was >80 % (Fig. 2e). As determined via in
situ hybridization, neoplastic cells were EBV-encoded RNA
(EBER)-positive (Fig. 2f). Although cytoplasmic κ and λ
light chains were not detected via in situ hybridization
(Fig. 2g, h), clonal IgH chain gene rearrangement was
detected via polymerase chain reaction (PCR) (Fig. 2i).
Because the patient had no immunosuppressive condition
other than advanced age, he was diagnosed with PBL-E,
and surgical excision was scheduled.
After the biopsy, however, the tumor began to de-
crease in size. Surgical excision was performed 40 days
after the biopsy, although the exophytic tumor had ap-
parently disappeared (Fig. 1c). A surgical specimen
showed infiltration of CD138-positive plasma cells and
polymorphic inflammatory cells, including numerous
foamy macrophages (Fig. 3a, b). The plasma cells
expressed cytoplasmic immunoglobulins (κ and λ light
chain) with no light chain restriction, and the results of
EBER in situ hybridization were negative (Fig. 3c–e).
There was no evidence of a residual neoplastic lesion.
Serological testing for EBV was performed 4 days after
surgery, and EBV-DNA was detected in whole blood via
real-time PCR (Table 1). FDG-PET imaging 102 days
after the biopsy showed no abnormal FDG uptake
(Fig. 1d), suggesting that the neoplastic lesion had clinic-
ally disappeared completely. The patient has thus far
been followed-up for 5 months with no sign of relapse.
Conclusions
PBL is histologically highly aggressive with a high mitotic
index [1, 2]. However, the plasmablastic tumor cells in this




Fig. 1 Clinical photographs and imaging data. Clinical photographs (a,
c) and positron emission tomography/computed tomography (PET/CT)
imaging (b, d) of the lesion. Initial presentation (a, b), 40 days after
biopsy when surgery was performed (c), and 102 days after biopsy (d).
The exophytic tumor had clinically disappeared
Table 1 Serological tests for EBV and real-time PCR for EBV-DNA
in whole blood
Variable At biopsy Four days after surgerya Reference (range)
VCA-IgG (titer) 320 80 <10
VCA-IgA (titer) <10 NA <10
VCA-IgM (titer) <10 <10 <10
EA-DR-IgG (titer) <10 NA <10
EA-DR-IgA (titer) <10 NA <10
EBNA (titer) 20 20 <10
EBV-DNA
(copies/μgDNA)
NA 3.7 x 10^2 <1 × 10^2.5
aDay 44 after biopsy
VCA viral capsid antigen, EA-DR early antigen-diffuse and restrict complex,
EBNA Epstein-Barr virus nuclear antigen, EBV Epstein-Barr virus, NA
not available
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tumor treatment after biopsy. A previous report described
five cases of age-related EBV-positive mucocutaneous
ulcers (EBV-MCUs) that spontaneously regressed without
treatment (Table 2) [8]. Interestingly, the PBL-E in our
case shares clinical characteristics with these EBV-MCUs,
such as old age, mucosa site, a well-circumscribed lesion,
ulcer formation, EBV infection, Stage I disease, and a self-
limited clinical course [8]. EBV-MCUs are associated with
immunosuppressive conditions, such as immunosenes-
cence due to aging, and are considered an indolent EBV-
induced lymphoproliferative disorder (LPD) rather than
overt lymphomas [8]. Thus far, they have not been associ-
ated with HIV infection, and histologically, they contain
polymorphous B-cells, including plasmacytoid apoptotic
cells and immunoblasts, showing plasmacytic differenti-
ation [8].
Because the PBL-E in our case closely resembles an
EBV-MCU, we suggest that it should be considered as an
indolent EBV-associated B-cell LPD rather than a com-
mon aggressive PBL. It would, however, be considered an
atypical EBV-associated LPD owing to its distinctive
morphology and immunophenotype. Monomorphically
proliferating large lymphoid cells expressing B cell anti-
gens such as CD20 and CD79a are often seen in EBV-
associated LPDs [9]. In contrast, the large neoplastic cells
observed in our case, which had abundant cytoplasm and
prominent nucleoli, expressed CD138 but not CD20 or
CD79a. Although necrosis and giant cells resembling
Hodgkin and Reed/Sternberg cells are often observed in
EBV-associated LPDs, they were not observed in the PBL-
E in our case [9].
Similar to our study, a previous report indicated that
indolent Stage I PBL-E tumors in three elderly patients
had clinical features resembling those of EBV-MCUs
(Table 2) [3]. Because these patients received multi-agent
chemotherapy soon after diagnosis, it is not known
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Fig. 2 Histology and polymerase chain reaction (PCR) analysis of the lesion at initial presentation. Hematoxylin and eosin staining (a, b). (a) Original
magnification, ×100. (b) Original magnification, ×400. Immunohistochemistry for CD20 (c), CD138 (d), and Ki-67 (e) (original magnification, ×400). In situ
hybridization analyses for Epstein-Barr virus-encoded RNA (EBER) (f) and immunoglobulin κ (g) and λ (h) light chain (original magnification, ×400). PCR
analysis for immunoglobulin heavy chain rearrangements (i). The lesion was a solid tumor with an ulcertic surface (a). Immunoblastic cells with prominent
nucleoli (b) were negative for CD20 (c) but positive for CD138 and EBER (d, f) with a high Ki-67 index (e). Cytoplasmic immunoglobulin light chain was
absent (e, g). Monoclonal IgH chain gene rearrangement was demonstrated (i)
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whether their tumors would have regressed spontan-
eously. To our knowledge, we are the first to report spon-
taneous regression of a PBL-E. More studies are required
to determine the biological features of PBL-E tumors with
characteristics similar to those seen in indolent EBV-
associated LPDs.
EBV inhibits apoptosis and promotes pathogenesis in
EBV-associated LPDs [8]. Although the latency status of
EBV in EBV-associated LPDs is usually type II or III, the
EBV latency status in our case was type I, in agreement
with a previous report of PBL-E [3]. One possible mech-
anism of the spontaneous regression of the PBL-E is
mobilization of the immune system against EBV. In our
case, the viral capsid antigen-IgG titer in serum decreased
from 1:320 before regression to 1:80 after regression. This
change, however, most likely had no significant effect on
regression because both titers were within the low range.
MYC translocation is a negative prognostic factor for
and contributes to the pathogenesis of PBLs [2] including
PBL-E [3]. In our case, however, the c-Myc protein was
not highly expressed, and IgH/MYC translocations were
not detected via fluorescence in-situ hybridization. The
absence of this translocation may account at least in part
for the indolent clinical course of the PBL-E in our case.
In contrast to our case, three previously reported cases
of PBL showing spontaneous regression were clearly asso-
ciated with a specific immunodeficiency (e.g., HIV infec-
tion [10, 11] and methotrexate administration [12]). The
spontaneous regression in these cases may be related to
the patient’s restoration of immune function secondary to
anti-HIV treatment or reduced dosage of an immunosup-
pressive agent. Therefore, the mechanisms underlying the
spontaneous regression in our case may differ from those
in these previous cases.
In conclusion, PBL-E can partially follow, albeit rarely, a
self-limited clinical course without anti-neoplastic therapy.




Fig. 3 Histology of the surgical specimen. Hematoxylin and eosin
staining (original magnification, ×200) (a). Immunohistochemical CD138
staining (original magnification, ×400) (b). In situ hybridization analyses
for Epstein-Barr virus-encoded RNA (EBER) (c), and immunoglobulin κ (d)
and λ (e) light chain (original magnification, ×400). Plasma cell infiltration
was observed along with polymorphic inflammatory cells including
numerous foam cells (a, b). The plasma cells were negative for EBER but
expressed cytoplasmic immunoglobulin κ and λ light chain
Table 2 Localized indolent EBV-associated lymphoproliferative disorder/lymphoma in the eldery
No Age/Sex Site Pathologic diagnosis HIV infection Treatment Outcome Follow-up(months) IGH/MYC Reference No.
(case No.)
1 80/M Gingiva PBL-E - None SR Alive (8) N Present case
2 79/M Skin of check EBV-MCU - None SR DNED (25) NA 8 (1)
3 82/M Lip, Skin EBV-MCU - None SR NA NA 8 (2)
4 76/M Tongue EBV-MCU - None SR Alive (12) NA 8 (7)
5 68/F Tongue EBV-MCU - None SR Alive (36) NA 8 (13)
6 88/M Skin of chest EBV-MCU - None SR Alive (3) NA 8 (16)
7 64/M Nasal cavity PBL-E - CHOP + RT CR Alive (55) N 3 (4)
8 70/M Gingiva PBL-E - CHOP CR Alive (23) R 3 (6)
9 60/M Nasal cavity PBL-E - CHOP Under therapy Alive (1) N 3 (8)
M male, F female, PBL-E plasmablastic lymphoma of the elderly, EBV-MCU Epstein-Barr virus-positie mucocutaneous ulcer, HIV human immunodeficiency virus,
CHOP cyclophosphamide-adriamycin-vincristine-prednisone, RT radiotherapy, SR spontaneous regression, CR complete response, DNED died no evidence of
disease, NA not available, N negative, R rearrangement
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characteristics similar to those of indolent EBV-associated
LPDs and should be recognized as a unique clinicopatho-
logical entity distinct from common aggressive PBL.
Consent
Written informed consent was obtained from the patient
for publication of this report and any accompanying
images.
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